Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC11A2 | P49281 | 5/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2568095 | 0.81 | GRIN2D (0.38) | SLC11A2KDM5AKDM4CKDM2BKDM5B | |
| SCHEMBL30356814 | 0.64 | CCR1 (0.50) | PARP1CCR1CCR5CCR8MEN1 | |
| SCHEMBL17310064 | 0.62 | LRRK2 (0.58) | PARP1CCR1CCR5CCR8GAA | |
| SCHEMBL8249813 | 0.62 | VHL (0.69) | — | |
| SCHEMBL2876435 | 0.62 | NCF1 (0.58) | CCR1CCR5CCR8HRH3 | |
| SCHEMBL24920393 | 0.61 | CCR1 (0.53) | CCR1CCR5CCR8MAPTRAB9A | |
| Hydrochloric Acid SCHEMBL31061466 | 0.61 | NCF1 (0.57) | CCR1CCR5CCR8HRH3 | |
| SCHEMBL21274954 | 0.60 | CCR1 (0.52) | CCR1CCR5CCR8MAPTRAB9A | |
| SCHEMBL30839382 | 0.60 | CCR1 (0.52) | CCR1CCR5CCR8MAPTNOS3 | |
| SCHEMBL30230148 | 0.60 | HRH4 (0.56) | CCR1CCR5CCR8MAPTNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697731-B2 | Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof | SANOFI (FR) | 2014-04-15 | — | — | US | claimed |
| US-20110301148-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-08 | — | — | US | claimed |
| EP-2382215-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-02 | — | — | EP | claimed |
| WO-2010076525-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | WO | claimed |
| US-9359329-B2 | Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof | SANOFI (FR) | 2016-06-07 | — | — | US | disclosed |
| US-9359329-B2 | Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof | SANOFI (FR) | 2016-06-07 | — | — | US | disclosed |
| US-20160137627-A9 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2016-05-19 | — | — | US | disclosed |
| US-20160137627-A9 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2016-05-19 | — | — | US | disclosed |
| US-20140194470-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-07-10 | — | — | US | disclosed |
| US-20140194470-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-07-10 | — | — | US | disclosed |
| US-8697731-B2 | Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof | SANOFI (FR) | 2014-04-15 | — | — | US | disclosed |
| US-20110301148-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-08 | — | — | US | disclosed |
| US-20110301148-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-08 | — | — | US | disclosed |
| EP-2382215-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010076525-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137627-A9 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | NR3C2, NR3C1, NR5A2 | SLC11A2 1916/4885PARP1 3347/4885CCR1 194/4885 |
| US-20140194470-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | NR3C2, NR3C1, NR5A2 | SLC11A2 1916/4885PARP1 3347/4885CCR1 194/4885 |
| US-20110301148-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | NR3C2, NR3C1, NR5A2 | SLC11A2 1916/4885PARP1 3347/4885CCR1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.